BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the initiation of clinical study of the HIF-1 alpha antagonist (EZN-2968) evaluating an additional dosing schedule. The open-label, non-randomized Phase 1 study is designed to evaluate the safety, tolerability, and pharmacokinetics of the HIF-1 alpha antagonist in a daily for 5 days schedule in approximately 30 patients with advanced solid tumors or lymphoma.
